Ftse Mib
33.707,21
0,00%
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
61.574,16
-0,38%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kinnate Biopharma Inc (KNTE) Kinnate Biopharma Inc (KNTE) Notizie

Kinnate Biopharma Inc

KNTE
2,65
0,00 (0,00%)
25 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/4/202415:00GLOBEXOMA Corporation Announces Closing of Tender Offer
19/3/202421:05GLOBEXOMA Announces Calculation of Additional Price Per Share and..
05/3/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202423:27EDGAR2Form SC 14D9 - Solicitation, recommendation statements
01/3/202414:53EDGAR2Form SC14D9C - Written communication relating to third party..
01/3/202414:50EDGAR2Form 8-K - Current report
01/3/202414:35PRNUSKinnate Biopharma Inc. Sells Its Investigational Pan-RAF..
01/3/202414:30GLOBEKinnate Biopharma Inc. Sells Its Investigational Pan-RAF..
21/2/202412:01EDGAR2Form SC14D9C - Written communication relating to third party..
16/2/202423:57PRNUSALERT: Rowley Law PLLC is Investigating Proposed Acquisition..
16/2/202416:46PRNUSKuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to..
16/2/202415:10EDGAR2Form 8-K - Current report
16/2/202414:00GLOBEXOMA Enters into Agreement to Acquire Kinnate Biopharma for..
14/2/202415:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
16/1/202422:05EDGAR2Form 8-K - Current report
05/12/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202315:00EDGAR2Form 8-K - Current report
09/11/202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:14EDGAR2Form 8-K - Current report
09/11/202322:05GLOBEKinnate Biopharma Inc. Reports Third Quarter 2023 Financial..
18/9/202322:28EDGAR2Form 8-K - Current report
18/9/202322:10GLOBEKinnate Biopharma Inc. Announces Pipeline Updates, Strategic..
06/9/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202322:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:16EDGAR2Form 8-K - Current report
08/8/202322:05GLOBEKinnate Biopharma Inc. Reports Second Quarter 2023 Financial..
28/7/202322:06EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 2,65

La tua Cronologia

NASDAQ
KNTE
Kinnate Biopharma
LSE
HMAD
Hsbc Far East $
LSE
MF61
So_stoxx50_mf61
AMEX
AMBI
Ambipar Emergency Response
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network